GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 188 Impairment charge for the year ended March 31, 2020 included provision in respect of certain capital work-in-progress amounting to ` 26,31.00 lakhs due to abandonment of assets. Capital work-in-progress: ( ` in lakhs) Particulars As at March 31, 2021 As at March 31, 2020 Opening Balance 120,12.15 1002,64.42 Additions 20,95.67 99,62.37 Less: Capitalisation (57,62.89) (869,71.22) Asset held for sale (70,23.50) - Impairment (Refer Note 3(b) above) - (112,43.42) Closing Balance 13,21.43 120,12.15 Note 4 : Investment Property ( ` in lakhs) Particulars As at March 31, 2021 As at March 31, 2020 Gross carrying amount Opening gross carrying amount/ Deemed cost 2,26.41 2,26.41 Additions - - Closing gross carrying amount 2,26.41 2,26.41 Accumulated Depreciation Opening Accumulated Depreciation 77.08 62.70 Depreciation 14.38 14.38 Closing Accumulated Depreciation 91.46 77.08 Net carrying amount 1,34.95 1,49.33 (i) Amounts recognised in the Statement of Profit and Loss for investment property ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 Depreciation (14.38) (14.38) Amount recognised in the Statement of Profit and Loss (net) (14.38) (14.38) (ii) Estimation of fair value The Group has three properties (March 31, 2021: three properties) that have been considered as Investment Properties. These comprise of three vacant land sites (March 31, 2020: three vacant land sites) that are not in operational use at present. In the view of the management, the fair market value of the land sites is not reliably measurable as there are very few recent transactions of comparable composition of these properties in the market. Further, the fair market value will be subject to numerous municipal deductions dependent upon the current use and intended use of the property. Based on